Artiva Biotherapeutics Files 8-K for Bylaw Amendments
Ticker: ARTV · Form: 8-K · Filed: Jul 22, 2024 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 8-K |
| Filed Date | Jul 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, bylaws
TL;DR
ARTIVA files 8-K for bylaw changes and financials. Nothing major yet.
AI Summary
Artiva Biotherapeutics, Inc. filed an 8-K on July 22, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorporated in Delaware, is in the biological products sector and is headquartered in San Diego, California.
Why It Matters
This filing indicates potential internal governance changes or updates to the company's operational framework, which could impact its strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural, reporting standard corporate actions without immediate financial or operational distress.
Key Numbers
- 001-42179 — SEC File Number (Identifies the company's filing history with the SEC.)
- 863614316 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- July 22, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) (industry) — Standard Industrial Classification
FAQ
What specific amendments were made to Artiva Biotherapeutics' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these changes are not provided in the summary text of the 8-K.
What is the primary business of Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code.
When was this Form 8-K filed?
This Form 8-K was filed on July 22, 2024.
Where are Artiva Biotherapeutics' principal executive offices located?
The principal executive offices of Artiva Biotherapeutics are located at 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
Does this filing relate to any financial statements?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information, alongside amendments to articles of incorporation or bylaws.
Filing Stats: 602 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-07-22 16:19:58
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ARTV Nasdaq Glo
Filing Documents
- d863184d8k.htm (8-K) — 18KB
- d863184dex31.htm (EX-3.1) — 27KB
- 0001193125-24-182231.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Artiva Biotherapeutics, Inc. By: /s/ Fred Aslan, M.D. Fred Aslan, M.D. President and Chief Executive Officer Dated: July 22, 2024